Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29882921)

  • 1. Distinct DNA Methylation Profiles in Ovarian Tumors: Opportunities for Novel Biomarkers.
    Losi L; Fonda S; Saponaro S; Chelbi ST; Lancellotti C; Gozzi G; Alberti L; Fabbiani L; Botticelli L; Benhattar J
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype.
    Kolbe DL; DeLoia JA; Porter-Gill P; Strange M; Petrykowska HM; Guirguis A; Krivak TC; Brody LC; Elnitski L
    PLoS One; 2012; 7(3):e32941. PubMed ID: 22403726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
    Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiling of esophageal adenocarcinoma using Methylation Ligation-dependent Macroarray (MLM).
    Guilleret I; Losi L; Chelbi ST; Fonda S; Bougel S; Saponaro S; Gozzi G; Alberti L; Braunschweig R; Benhattar J
    Biochem Biophys Res Commun; 2016 Oct; 479(2):231-237. PubMed ID: 27634218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array.
    Yoon MS; Suh DS; Choi KU; Sol MY; Shin DH; Park WY; Lee JH; Jeong SM; Kim WG; Shin NR
    Oncol Rep; 2010 Oct; 24(4):917-25. PubMed ID: 20811671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
    Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
    Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter hypermethylation profile of ovarian epithelial neoplasms.
    Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
    Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.
    Houshdaran S; Hawley S; Palmer C; Campan M; Olsen MN; Ventura AP; Knudsen BS; Drescher CW; Urban ND; Brown PO; Laird PW
    PLoS One; 2010 Feb; 5(2):e9359. PubMed ID: 20179752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
    Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.
    Dai W; Teodoridis JM; Zeller C; Graham J; Hersey J; Flanagan JM; Stronach E; Millan DW; Siddiqui N; Paul J; Brown R
    Clin Cancer Res; 2011 Jun; 17(12):4052-62. PubMed ID: 21459799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
    Ma L; Zhang JH; Liu FR; Zhang X
    Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets.
    Wu Q; Lothe RA; Ahlquist T; Silins I; Tropé CG; Micci F; Nesland JM; Suo Z; Lind GE
    Mol Cancer; 2007 Jul; 6():45. PubMed ID: 17623056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    Schmid G; Notaro S; Reimer D; Abdel-Azim S; Duggan-Peer M; Holly J; Fiegl H; Rössler J; Wiedemair A; Concin N; Altevogt P; Marth C; Zeimet AG
    BMC Cancer; 2016 Feb; 16():102. PubMed ID: 26879132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of O⁶-methyguanine-DNA methyltransferase by promoter hypermethylation: association of epithelial ovarian carcinogenesis in specific histological types.
    Roh HJ; Suh DS; Choi KU; Yoo HJ; Joo WD; Yoon MS
    J Obstet Gynaecol Res; 2011 Jul; 37(7):851-60. PubMed ID: 21450028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.